Strong biostatistical support is essential to the design and execution of efficient, high quality clinical trials. Our trained, qualified, and experienced biostatisticians can help take your clinical trial or observational study from concept all the way through final analysis and reporting.
Our Legacy. Our Future.
Founded by biostatisticians in 1977, we’ve always been statistics-driven. Today, we have more than 90 biostatisticians at Emmes spread across the globe. Our biostatisticians have advanced degrees, including around a third with PhD’s in statistics, biostatistics, or epidemiology.
Our biostatisticians can optimize your study’s design and performance through advanced statistical approaches, innovative adaptive study designs and sophisticated analytical methodologies, then build them into your trial’s Statistical Analysis Plan.
In addition, our legacy in biostatistics has ensured that biostatistical input is embedded into all aspects of the clinical trial life cycle at Emmes and our close collaboration with clinical operations and data
management ensures the right data is being collected in a high quality manner allowing for efficient analysis and reporting as well as ease of interpretation.
And our bioinformatics experts can deliver a variety of solutions when your trial involves analysis of large volumes of “omics” data analysis. Those include machine learning, advanced data visualization, clinical trial data management, pathways analysis, scalable cloud computing and reproducible data analysis methods.
All of this expertise has already helped to cure rare diseases and provide better patient treatments.
Together, we can optimize your trial, data quality and study results, from initial study planning to protocol writing, study design through regulatory submissions and publications.
Peter Dawson, Ph.D.
We offer you accountability and ownership, access to our team leaders and experts and a shared passion for biostatistics for the biological and health sciences.
We have managed biostatistics for over 1,000 clinical trials, from simple Phase I-II to highly complex, global Phase II-IV trials and registries. Our team has experience with adaptive designs, independent reporting to Data Monitoring Committees (DMCs) and Data and Safety Monitoring Boards (DSMBs), production of CDISC compliant deliverables such as SDTM and ADaM datasets, metadata, and reviewer’s guides and PK/PD analyses.
Our experience across numerous therapeutic areas is complemented by specialist expertise in vaccines, infectious diseases, substance use disorder, neurology/mental health, ophthalmology, oncology, maternal and child health, transplant, allergies, autoimmune disorders and gene/cell therapies.
To learn more about how Emmes can help you with biostatistical analysis, please contact us.